Vertex Pharmaceuticals (NasdaqGS:VRTX) reported positive Phase 3 RAINIER data for povetacicept in IgA nephropathy, meeting ...

Company shares surged in after-market trading on results for a drug Vertex acquired in a multibillion-dollar deal and sees as ...

Vertex Pharmaceuticals will soon try to commercialize another medicine. The new therapy targets the same market as four of its other products. Using a priority review voucher is an expensive choice, ...

Philip Nadeau TD Cowen, Research Division. Good morning, and welcome once again to TD Cowen's 46th Annual Healthcare Conference. I'm Phil Nadeau, one of the biotech analysts here ...

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs), today announced a global, multi-target license and option agreement ...

Total revenues of $666.8 million for the full year 2024, representing a 16.5% year-over-year increase, indicating strong business growth. Cloud revenues grew by 28.6% year-over-year for the full year ...

On Tuesday, 03 March 2026, Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) presented at the TD Cowen 46th Annual Health Care Conference, outlining its strategic vision and pipeline progress. CEO Reshma ...

Vertex is a leader in the billion-dollar cystic fibrosis treatment market. The company recently expanded beyond this specialty area with a newly approved blood disorder therapy. Vertex's plans to ...